Trial intelligence / Profile preview

Retrovir, HIVID, and Wellferon in HIV Infection

NCT00002086Phase 2

Key facts

Status: Completed
Countries: 1
Sponsor: GSK
Modality: Cytokines & Interferons

Drugs: interferon alfa-n1
Conditions: human immunodeficiency virus infection (HIV)

Overview

Phase 2, randomised, open-label trial of interferon alfa-n1 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by GSK. Primary endpoints: Complete Response (CD4 >= 800 cells/mm3 for > 24 weeks) and Antiviral Effect (Quantitative Viral Load). Status: completed.

Design

2 arms

Study design: RandomizedOpen-label

Retrovir + HIVID
Zidovudine + Zalcitabine
Retrovir + HIVID + Wellferon
Zidovudine + Zalcitabine + Interferon alfa-n1

Who it enrols

Patients with HIV infection and CD4 counts between 300 and 500 cells/mm3, with no more than 3 months of prior antiretroviral therapy.

Endpoints

Primary

Complete Response (CD4 >= 800 cells/mm3 for > 24 weeks)24 weeks
Antiviral Effect (Quantitative Viral Load)

Secondary

CD4 Count Maintenance or Increase
Disease Progression to AIDS-Defining Illness
Secondary Measures of Clinical Status
Serum p24 Antigen
Safety and Tolerance

Beyond the preview

Go deeper on NCT00002086.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00002086.